Сartalaх
Biologically active food supplement СARTALAХ® is a peptide complex containing amino acids: ala-
nine, glutamic acid, aspartic acid, which has a normalizing effect on the cells of the immune system.
СARTALAХ® is available in tablets or capsules with an active substance content of 0.100 mg.
Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tis-
sues from which they are isolated. They improve the trophism of cartilaginous tissue cells and regulate
metabolic processes in them, reducing the risk of various joint and spine diseases. Thus, it is possible
to extrapolate the efficiency of СARTALAХ® in restoring cartilaginous tissue function in patients with
inflammatory and dystrophic-degenerative diseases of the musculoskeletal system.
Clinical trials of СARTALAХ® took place at the Medical Center of the Saint Petersburg Institute of
Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Scienc-
es in patients with osteoarthritis of joints, osteochondrosis of the spine, and osteoporosis during the
period from October 2005 to February 2006.
СARTALAХ® was administered to patients orally 10-15 minutes before meals, 1-3 tablets 2-3 times
a day for 30-45 days, depending on the severity of the pathological process.
The treatment and rehabilitation of patients with degenerative-dystrophic diseases of the joints and
spine, occurring with irreversible, progressive changes, is a complex problem that is most urgent in
geriatric practice (2, 3).
Drug therapy for degenerative-dystrophic diseases of the joints and spine includes the use of various
drugs of symptomatic and pathogenic action (1):
- Analgesics and anti-inflammatory drugs (analgin, novocaine blockade, rheopyrin, indomethacin,
brufen);
- Antihistamines (diphenhydramine, pipolfen);
- Drugs, which improve peripheral blood circulation (pachikarpin, platifillin);
- Biostimulants (rumalon, aloe, vitreous body, ATP);
- Enzyme medication (lidase, ronidase);
- Anabolic steroids (neurabol, retabolil);
- etc.
CLINICAL CHARACTERISTICS OF PATIENTS
Thirty-three patients diagnosed with osteoarthritis, osteochondrosis, or osteoporosis participated in
the clinical trials of СARTALAХ®. Ten patients with osteoarthritis of the knee joints (7 men, 3 women),
15 patients with osteochondrosis of the spine (6 men, 9 women), and 8 patients with osteoporosis (8
women). The patients’ age ranged from 45 to 78 years.
The control group included 31 patients with similar diagnoses, gender, and age. You can see the dis-
tribution of patients by diagnosis, sex, and age in Table 1.
Patients with osteoarthritis of the knee joints complained of pain and limitation of flexion and exten-
sion in the joints when walking. Representatives of the senior age group suffered from deformity of
the joints, atrophy of the femoral muscles, and weakening of the ligamentous apparatus of the joints.
Patients in the second group often noted the pain in the lower back with irradiation along the sciatic
nerve, significantly increasing with a change in body position, walking, and physical activity.
Osteoporotic patients complained of frequent bone fractures arising from minor trauma or even for
no apparent reason.
In patients of the primary and control groups, the duration of the disease ranged from 5 to 20 years.
A progressive dynamic of the development of the pathological process was noted.
All patients previously received analgesics and anti-inflammatory drugs for a long time, the use of
which resulted in a short-term therapeutic effect, requiring an increase in the dose of drugs for the
course of treatment and their prolonged use.
Patients in the control group received treatment using conventional drugs. In addition to traditional
medicines, patients of the primary group have been taking СARTALAХ® 2-3 capsules 2-3 times a day
before meals for 30-45 days.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.